Trials / Completed
CompletedNCT00703911
Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
A Prospective Observational Registry on the Use of NovoSeven® (Activated Recombinant Human Factor VIIa) for on Demand Treatment of Mild to Moderate Bleeds in Haemophilia A and B Patients With Inhibitors
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 102 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study was conducted in Africa, Europe, the Middle-East and South America. The primary objective of this registry was to observe the use of single dose and multi-dose use of activated recombinant human factor VII and to compare short-term outcomes, including effectiveness, safety, quality of life and treatment satisfaction with the approved treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | eptacog alfa (activated) | Treatment of patients experiencing bleeds at the discretion of the physician/caregiver |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2008-06-24
- Last updated
- 2017-01-11
- Results posted
- 2011-12-19
Locations
16 sites across 16 countries: Algeria, Austria, Belgium, Czechia, France, Germany, Italy, Netherlands, Poland, Portugal, Saudi Arabia, South Africa, Sweden, Turkey (Türkiye), United Kingdom, Venezuela
Source: ClinicalTrials.gov record NCT00703911. Inclusion in this directory is not an endorsement.